Stemline Therapeutics’ (STML) Buy Rating Reaffirmed at Cowen

Cowen reissued their buy rating on shares of Stemline Therapeutics (NASDAQ:STML) in a report issued on Sunday, AnalystRatings.com reports.

Several other research firms also recently commented on STML. Wedbush upgraded shares of Stemline Therapeutics from a neutral rating to an outperform rating in a research report on Friday. Zacks Investment Research upgraded shares of Stemline Therapeutics from a hold rating to a buy rating and set a $15.00 target price on the stock in a research report on Saturday, July 27th. HC Wainwright set a $35.00 target price on shares of Stemline Therapeutics and gave the stock a buy rating in a research report on Thursday, June 20th. BidaskClub downgraded shares of Stemline Therapeutics from a buy rating to a hold rating in a research report on Thursday, July 4th. Finally, ValuEngine lowered shares of Stemline Therapeutics from a buy rating to a hold rating in a report on Wednesday, May 15th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average target price of $23.50.

NASDAQ:STML traded down $0.55 during mid-day trading on Friday, hitting $14.31. 598,672 shares of the company’s stock were exchanged, compared to its average volume of 585,220. The stock’s 50 day moving average is $14.19. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.07 and a quick ratio of 5.03. Stemline Therapeutics has a fifty-two week low of $7.82 and a fifty-two week high of $17.85. The company has a market cap of $649.16 million, a price-to-earnings ratio of -4.79 and a beta of 1.29.

Stemline Therapeutics (NASDAQ:STML) last posted its earnings results on Friday, August 2nd. The biopharmaceutical company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.05. The business had revenue of $13.01 million for the quarter, compared to analyst estimates of $8.84 million. On average, analysts forecast that Stemline Therapeutics will post -2.09 earnings per share for the current year.

In other news, COO Kenneth Hoberman sold 25,817 shares of Stemline Therapeutics stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $14.27, for a total value of $368,408.59. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Ivan Bergstein sold 56,316 shares of Stemline Therapeutics stock in a transaction on Wednesday, June 26th. The shares were sold at an average price of $15.08, for a total transaction of $849,245.28. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 149,177 shares of company stock valued at $2,236,377. Company insiders own 13.10% of the company’s stock.

Several large investors have recently added to or reduced their stakes in STML. State Board of Administration of Florida Retirement System increased its stake in Stemline Therapeutics by 27.7% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 14,138 shares of the biopharmaceutical company’s stock worth $217,000 after acquiring an additional 3,070 shares during the last quarter. C WorldWide Group Holding A S increased its stake in Stemline Therapeutics by 139.6% in the 2nd quarter. C WorldWide Group Holding A S now owns 858,082 shares of the biopharmaceutical company’s stock worth $13,146,000 after acquiring an additional 500,000 shares during the last quarter. Candriam Luxembourg S.C.A. bought a new stake in Stemline Therapeutics in the 2nd quarter worth approximately $1,220,000. SG Americas Securities LLC bought a new stake in Stemline Therapeutics in the 2nd quarter worth approximately $104,000. Finally, Steward Partners Investment Advisory LLC bought a new stake in Stemline Therapeutics in the 2nd quarter worth approximately $67,000. Institutional investors own 78.78% of the company’s stock.

About Stemline Therapeutics

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

Read More: What is a stock portfolio tracker?

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.